27914462|t|Recombinant MHC Tetramers for Isolation of Virus - Specific CD8(+) Cells from Healthy Donors: Potential Approach for Cell Therapy of Posttransplant Cytomegalovirus Infection
27914462|a|Patients undergoing allogeneic hematopoietic stem cell transplantation have a high risk of cytomegalovirus reactivation, which in the absence of T-cell immunity can result in the development of an acute inflammatory reaction and damage of internal organs. Transfusion of the virus-specific donor T-lymphocytes represents an alternative to a highly toxic and often ineffective antiviral therapy. Potentially promising cell therapy approach comprises transfusion of cytotoxic T-lymphocytes, specific to the viral antigens, immediately after their isolation from the donor's blood circulation without any in vitro expansion. Specific T-cells could be separated from potentially alloreactive lymphocytes using recombinant major histocompatibility complex (MHC) multimers, carrying synthetic viral peptides. Rapid transfusion of virus - specific T-cells to patients has several crucial advantages in comparison with methods based on the in vitro expansion of the cells. About 30% of hematopoietic stem cell donors and 46% of transplant recipients at the National Research Center for Hematology were carriers of the HLA-A*02 allele. Moreover, 94% of Russian donors have an immune response against the cytomegalovirus (CMV). Using recombinant HLA-A*02 multimers carrying an immunodominant cytomegalovirus peptide (NLV), we have shown that the majority of healthy donors have pronounced T-cell immunity against this antigen, whereas shortly after the transplantation the patients do not have specific T-lymphocytes. The donor cells have the immune phenotype of memory cells and can be activated and proliferate after stimulation with the specific antigen. Donor lymphocytes can be substantially enriched to significant purity by magnetic separation with recombinant MHC multimers and are not activated upon cocultivation with the antigen -presenting cells from HLA - incompatible donors without addition of the specific antigen. This study demonstrated that strong immune response to CMV of healthy donors and prevalence of HLA-A*02 allele in the Russian population make it possible to isolate a significant number of virus-specific cells using HLA-A*02-NLV multimers. After the transfusion, these cells should protect patients from CMV without development of allogeneic immune response.
27914462	0	11	Recombinant	T001	C1514798
27914462	12	25	MHC Tetramers	T028	C0024518
27914462	30	39	Isolation	T061	C0204727
27914462	43	48	Virus	T005	C0042776
27914462	51	59	Specific	T080	C0205369
27914462	60	72	CD8(+) Cells	T025	C0242629
27914462	78	92	Healthy Donors	T080	C3898902
27914462	94	103	Potential	T080	C3245505
27914462	117	129	Cell Therapy	T061	C0302189
27914462	133	173	Posttransplant Cytomegalovirus Infection	T047	C0010823
27914462	174	182	Patients	T101	C0030705
27914462	194	204	allogeneic	T080	C1515895
27914462	205	244	hematopoietic stem cell transplantation	T061	C0472699
27914462	265	293	cytomegalovirus reactivation	T047	C1142560
27914462	319	334	T-cell immunity	T040	C1817907
27914462	371	398	acute inflammatory reaction	T033	C0333361
27914462	403	428	damage of internal organs	T037	C0332675
27914462	430	441	Transfusion	T061	C0086573
27914462	449	463	virus-specific	T080	C0205369
27914462	464	483	donor T-lymphocytes	T025	C0039194
27914462	515	527	highly toxic	T080	C1407029
27914462	538	549	ineffective	T078	C3242229
27914462	550	567	antiviral therapy	T061	C0280274
27914462	569	580	Potentially	T080	C3245505
27914462	591	603	cell therapy	T061	C0302189
27914462	623	634	transfusion	T061	C0086573
27914462	638	661	cytotoxic T-lymphocytes	T025	C0039195
27914462	663	671	specific	T080	C0205369
27914462	679	693	viral antigens	T129	C0003342
27914462	719	728	isolation	T061	C0204727
27914462	738	763	donor's blood circulation	T039	C0005775
27914462	776	794	in vitro expansion	T080	C1533691
27914462	796	804	Specific	T080	C0205369
27914462	805	812	T-cells	T025	C0039194
27914462	837	848	potentially	T080	C3245505
27914462	849	873	alloreactive lymphocytes	T025	C0024264
27914462	880	891	recombinant	T001	C1514798
27914462	892	924	major histocompatibility complex	T028	C0024518
27914462	926	929	MHC	T028	C0024518
27914462	931	940	multimers	T104	C1979934
27914462	951	975	synthetic viral peptides	T116	C0597551
27914462	983	994	transfusion	T061	C0086573
27914462	998	1003	virus	T005	C0042776
27914462	1006	1014	specific	T080	C0205369
27914462	1015	1022	T-cells	T025	C0039194
27914462	1026	1034	patients	T101	C0030705
27914462	1106	1124	in vitro expansion	T080	C1533691
27914462	1132	1137	cells	T025	C0007634
27914462	1152	1165	hematopoietic	T169	C0229601
27914462	1166	1182	stem cell donors	T080	C3898902
27914462	1194	1215	transplant recipients	T101	C0376387
27914462	1223	1262	National Research Center for Hematology	T093	C1708333
27914462	1284	1299	HLA-A*02 allele	T028	C0555908
27914462	1318	1325	Russian	T098	C0337816
27914462	1326	1332	donors	T080	C3898902
27914462	1341	1356	immune response	T042	C0301872
27914462	1369	1384	cytomegalovirus	T005	C0010825
27914462	1386	1389	CMV	T005	C0010825
27914462	1398	1409	recombinant	T001	C1514798
27914462	1410	1418	HLA-A*02	T028	C0555908
27914462	1419	1428	multimers	T104	C1979934
27914462	1441	1455	immunodominant	T080	C0205556
27914462	1456	1479	cytomegalovirus peptide	T116	C0030956
27914462	1481	1484	NLV	T116	C0030956
27914462	1522	1536	healthy donors	T080	C3898902
27914462	1553	1568	T-cell immunity	T040	C1817907
27914462	1582	1589	antigen	T129	C0003320
27914462	1617	1632	transplantation	T061	C0040732
27914462	1637	1645	patients	T101	C0030705
27914462	1658	1666	specific	T080	C0205369
27914462	1667	1680	T-lymphocytes	T025	C0039194
27914462	1686	1697	donor cells	T025	C0007634
27914462	1707	1723	immune phenotype	T032	C0031437
27914462	1727	1739	memory cells	T025	C0682639
27914462	1751	1760	activated	T043	C2259058
27914462	1765	1776	proliferate	T043	C0596290
27914462	1804	1812	specific	T080	C0205369
27914462	1813	1820	antigen	T129	C0003320
27914462	1822	1839	Donor lymphocytes	T033	C1395724
27914462	1861	1869	enriched	UnknownType	C0681540
27914462	1885	1891	purity	T081	C1882508
27914462	1895	1914	magnetic separation	T059	C0599662
27914462	1920	1931	recombinant	T001	C1514798
27914462	1932	1935	MHC	T028	C0024518
27914462	1936	1945	multimers	T104	C1979934
27914462	1958	1967	activated	UnknownType	C0678666
27914462	1973	1986	cocultivation	T059	C0282547
27914462	1996	2003	antigen	T129	C0003320
27914462	2016	2021	cells	T025	C0007634
27914462	2027	2030	HLA	T116,T129	C0019721
27914462	2033	2052	incompatible donors	T098	C0013018
27914462	2077	2085	specific	T080	C0205369
27914462	2086	2093	antigen	T129	C0003320
27914462	2100	2105	study	T062	C2603343
27914462	2131	2146	immune response	T042	C0301872
27914462	2150	2153	CMV	T005	C0010825
27914462	2157	2171	healthy donors	T080	C3898902
27914462	2190	2205	HLA-A*02 allele	T028	C0555908
27914462	2213	2231	Russian population	T098	C1257890
27914462	2284	2298	virus-specific	T080	C0205369
27914462	2299	2304	cells	T025	C0007634
27914462	2311	2323	HLA-A*02-NLV	T028	C0555908
27914462	2324	2333	multimers	T104	C1979934
27914462	2345	2356	transfusion	T061	C1879316
27914462	2364	2369	cells	T025	C0007634
27914462	2385	2393	patients	T101	C0030705
27914462	2399	2402	CMV	T005	C0010825
27914462	2426	2436	allogeneic	T080	C1515895
27914462	2437	2452	immune response	T042	C0301872